



*Sayyid RK, et al. Active surveillance in favorable intermediate-risk prostate cancer patients: Predictors of deferred intervention and treatment choice*

Southeast	0.84	0.73–0.97	<b>0.020</b>	0.97	0.75–1.25	0.82	0.56	0.30–1.09	0.058
Midwest	1.78	1.32–2.44	<b>&lt;0.001</b>	1.43	0.95–2.18	0.093	1.01	0.42–2.81	0.98
West	0.91	0.80–1.04	0.17	0.89	0.71–1.10	0.28	0.80	0.44–1.40	0.45
SES quartiles (reference: 1 [lowest])									
2	1.29	1.10–1.51	<b>0.002</b>	1.26	0.99–1.58	0.052	1.53	0.81–2.98	0.20
3	1.20	1.03–1.39	<b>0.015</b>	1.01	0.81–1.26	0.94	0.87	0.51–1.47	0.61
4 (highest)	1.82	1.55–2.13	<b>&lt;0.001</b>	1.46	1.14–1.87	<b>0.003</b>	1.61	0.88–3.02	0.13
PCa as first cancer diagnosis (reference: previously diagnosed with other cancer)	1.13	0.92–1.37	0.25	1.41	1.03–1.91	<b>0.028</b>	0.90	0.28–2.18	0.85
PSA (references: 0–5 ng/ml for groups 1 and 3; 10–15 ng/ml for group 2)									
5–10 ng/ml	1.00	0.85–1.16	0.95				1.05	0.64–1.66	0.84
10–20 ng/ml				1.25	0.83–1.86	0.27			
Percent cores positive (reference: 0–12.5%)									
12.6–25.0%	1.13	0.97–1.32	0.13	1.18	0.97–1.44	0.10	1.03	0.55–1.92	0.93
25.1–37.5%	1.38	1.19–1.61	<b>&lt;0.001</b>	1.37	1.10–1.71	<b>0.005</b>	0.62	0.35–1.06	0.089
37.6–49.9%	1.37	1.15–1.65	<b>&lt;0.001</b>	1.81	1.27–2.64	<b>0.001</b>	0.75	0.37–1.56	0.43
cT stage (cT1 as reference for groups 1 and; cT2b for group 3)									
cT2a	3.07	2.56–3.72	<b>&lt;0.001</b>	4.29	3.06–6.17	<b>&lt;0.001</b>			
cT2c							17.7	11.4–27.3	<b>&lt;0.001</b>

CI: confidence interval; NA: not available; OR: odds ratio; PSA: prostate-specific antigen; SEER: Surveillance, Epidemiology, and End Results; SES: socioeconomic status.

*Sayyid RK, et al. Active surveillance in favorable intermediate-risk prostate cancer patients: Predictors of deferred intervention and treatment choice*

<b>Supplementary Table 2.</b> Predictors of receiving radical prostatectomy versus radiation therapy on univariable logistic regression analysis for favorable intermediate prostate cancer patients by subgroup									
	<b>GG2 favorable intermediate-risk cohort (group 1) (n=9224)</b>			<b>PSA 10–20 ng/ml favorable intermediate-risk cohort (group 2) (n=2552)</b>			<b>cT2b–c favorable intermediate-risk cohort (group 3) (n=8558)</b>		
<b>Variable</b>	<b>OR</b>	<b>95% CI</b>	<b>p</b>	<b>OR</b>	<b>95% CI</b>	<b>p</b>	<b>OR</b>	<b>95% CI</b>	<b>p</b>
Year of diagnosis (reference: 2010–11)									
2012–13	0.87	0.74–1.02	0.09	0.91	0.66–1.25	0.56	0.89	0.66–1.20	0.44
2014–15	0.95	0.81–1.11	0.53	0.90	0.64–1.27	0.56	0.94	0.67–1.33	0.71
Age at diagnosis (reference: 30–49 years)									
50–59	0.43	0.30–0.61	<b>&lt;0.001</b>	0.59	0.23–1.63	0.28	0.51	0.12–1.42	0.26
60–69	0.19	0.13–0.27	<b>&lt;0.001</b>	0.30	0.12–0.83	<b>0.01</b>	0.14	0.035–0.38	<b>&lt;0.001</b>
70–79	0.05	0.034–0.074	<b>&lt;0.001</b>	0.097	0.036–0.28	<b>&lt;0.001</b>	0.03	0.008–0.092	<b>&lt;0.001</b>
Race (reference: Caucasian)									
African American	0.44	0.35–0.54	<b>&lt;0.001</b>	0.44	0.27–0.68	<b>&lt;0.001</b>	0.87	0.60–1.31	0.50
Hispanic	1.31	1.02–1.66	<b>&lt;0.001</b>	1.15	0.74–1.74	0.52	1.05	0.65–1.81	0.84
Asia/Pacific Islander/American Indian/Alaska Native	1.19	0.88–1.60	0.23	0.86	0.48–1.46	0.60	0.68	0.40–1.28	0.20
Insurance status (reference: insured)									
Uninsured	1.44	0.73–2.62	0.26	0.89	0.26–2.33	0.84	1.81	0.40–32.1	0.56
Medicaid	0.61	0.38–0.92	0.024	0.60	0.28–1.15	0.15	0.51	0.28–0.96	<b>0.041</b>
Marital status (reference: married)									
Not married	1.52	1.28–1.81	<b>&lt;0.001</b>	1.26	0.91–1.76	0.17	2.02	1.47–2.73	<b>&lt;0.001</b>
SEER registry region (reference: Northeast)									
Southeast	1.03	0.85–1.25	0.75	1.34	0.86–2.12	0.20	0.82	0.56–1.20	0.31

*Sayyid RK, et al. Active surveillance in favorable intermediate-risk prostate cancer patients: Predictors of deferred intervention and treatment choice*

Midwest	2.74	2.13–3.50	< <b>0.001</b>	2.76	1.58–4.80	< <b>0.001</b>	1.05	0.61–1.88	0.86
West	1.60	1.48–1.89	< <b>0.001</b>	1.57	1.07–2.37	<b>0.026</b>	0.90	0.63–1.26	0.53
SES quartiles (reference: 1 [lowest])									
2	0.76	0.61–0.94	<b>0.013</b>	0.76	0.52–1.13	0.17	1.10	0.74–1.66	0.63
3	1.13	0.93–1.36	0.22	0.96	0.66–1.40	0.85	0.82	0.57–1.16	0.27
4 (highest)	1.21	1.01–1.46	<b>0.049</b>	0.94	0.63–1.38	0.75	1.22	0.83–1.80	0.32
PCa as first cancer diagnosis (reference: previously diagnosed with other cancer)	1.51	1.14–2.05	<b>0.005</b>	1.15	0.67–2.13	0.64	2.53	1.61–3.81	<0.001
PSA (references: 0–5 ng/ml for groups 1 and 3; 10–15 ng/ml for group 2)									
5–10 ng/ml	0.48	0.41–0.56	< <b>0.001</b>				1.06	0.78–1.43	0.70
10–20 ng/ml				1.41	0.68–3.42	0.40			
Percent cores positive (reference: 0–12.5%)									
12.6–25.0%	0.87	0.72–1.03	0.11	0.70	0.51–0.95	<b>0.025</b>	0.62	0.39–0.97	<b>0.038</b>
25.1–37.5%	0.52	0.44–0.63	< <b>0.001</b>	0.32	0.21–0.48	< <b>0.001</b>	0.34	0.22–0.51	< <b>0.001</b>
37.6–49.9%	0.40	0.32–0.50	< <b>0.001</b>	0.18	0.071–0.39	< <b>0.001</b>	0.33	0.20–0.53	< <b>0.001</b>
cT stage (cT1 as reference for groups 1 and; cT2b for group 3)									
cT2a	144.2	109.8–193.4	< <b>0.001</b>	234.8	141.1–413.3	< <b>0.001</b>			
cT2c							35.4	26.4–47.5	< <b>0.001</b>

CI: confidence interval; NA: not available; OR: odds ratio; PSA: prostate-specific antigen; SEER: Surveillance, Epidemiology, and End Results; SES: socioeconomic status